Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Targeting homologous recombination deficiency in uterine leiomyosarcoma

Fig. 4

Patient with HRD uLMS with no HR pathway gene mutations response to PARPi. A Timeline of uLMS227 patient history. Repeated from Fig. 1B for ease of reference. B computerised tomography images of the patient abdomen prior to (i) and 3 months after initiation of PARPi therapy (ii). C Immunohistochemistry panel showing concordant protein expression between primary patient sample and PDX. H&E = Haematoxylin and Eosin, α-SMA = alpha smooth muscle actin. Scale bars represent 200 μm. D Structural variants plot generated from WGS data of the uLMS227 PDX sample showing intra-chromosomal rearrangements. E Copy number profile generated from the uLMS227 PDX sample where total CN is shown in black and minor CN in red. F Methylation analysis of the BRCA1 and RAD51C promoters. Red lines indicate a 100% methylated control, blue lines indicated 0% methylated control and the green line represents the uLMS227 sample (both patient and PDX sample)

Back to article page